A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients

被引：0
|
作者：
Ibrahim, Ahmed [1 ]
Yousaf, Muhammad Abdullah [1 ]
Anwar, Zain [2 ]
Anum [3 ]
Batool, Maha [1 ]
Rehman, Mohammad [1 ]
Safdar, Omar A. [4 ]
Khattak, Zeeshan Ahmed [5 ]
Faraz, Fatima [1 ]
Khalid, Huma [1 ]
机构：
[1] Rawalpindi Med Univ, Rawalpindi, Pakistan
[2] Univ Sch, Hunting Valley, OH USA
[3] Faisalabad Med Univ, Faisalabad, Pakistan
[4] Univ Arizona, Tucson, AZ USA
[5] Shifa Int Hosp Ltd, Islamabad, Pakistan
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187691
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
    Patel, Kishan K.
    Zeidan, Amer M.
    Shallis, Rory M.
    Prebet, Thomas
    Podoltsev, Nikolai
    Huntington, Scott F.
    BLOOD ADVANCES, 2021, 5 (04) : 994 - 1002
  • [32] Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
    Cui, Jingying
    Chen, Xuexing
    Li, Chunfang
    Yan, Qiong
    Yuan, Guolin
    HEMATOLOGY, 2024, 29 (01)
  • [33] DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS
    Zannoni, L.
    Forte, D.
    Sartor, C.
    Cristiano, G.
    Nanni, J.
    Parisi, S.
    Zingarelli, F.
    Bandini, L.
    Testoni, N.
    Ottaviani, E.
    Paolini, S.
    Papayannidis, C.
    Cavo, M.
    Rutella, S.
    Curti, A.
    HAEMATOLOGICA, 2024, 109 : 74 - 75
  • [34] Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis
    Venditti, Adriano
    Hou, Jing-Zhou
    Fenaux, Pierre
    Jonas, Brian A.
    Vrhovac, Radovan
    Montesinos, Pau
    Garcia, Jacqueline S.
    Rizzieri, David
    Thirman, Michael J.
    Kotey, Stanley
    Potluri, Jalaja
    Dhalla, Mazaher
    Pullarkat, Vinod
    BLOOD, 2023, 142
  • [35] Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients
    Lu, Wenyi
    Chen, Xiangli
    Zang, Yuzhu
    Zhu, Zunmin
    Zhang, Wenhui
    Hai, Yanliang
    Chen, Yuqing
    Jiang, Li
    Xing, Yanyan
    Liu, Yuanbo
    Shi, Jie
    Gao, Zhenxing
    BLOOD, 2024, 144 : 6037 - 6037
  • [36] Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
    Borate, Uma
    Huang, Ying
    Li Welkie, Rina
    Swords, Ronan T.
    Traer, Elie
    Stein, Eytan M.
    Lin, Tara L.
    Madanat, Yazan F.
    Patel, Prapti A.
    Collins, Robert H.
    Baer, Maria R.
    Duong, Vu H.
    Blum, William
    Arellano, Martha L.
    Stock, Wendy
    Odenike, Olatoyosi
    Redner, Robert L.
    Kovacsovics, Tibor J.
    Deininger, Michael W.
    Zeidner, Joshua F.
    Olin, Rebecca
    Smith, Catherine C.
    Foran, James M.
    Schiller, Gary J.
    Curran, Emily K.
    Koenig, Kristin L.
    Heerema, Nyla A.
    Chen, Timothy
    Martycz, Molly
    Stefanos, Mona
    Marcus, Sonja Gullen
    Druker, Brian J.
    Levine, Ross L.
    Burd, Amy
    Rossenber, Leohard
    Yocum, Ashley Owen
    Mims, Alice
    Byrd, John C.
    BLOOD, 2024, 144 : 4324 - 4326
  • [37] A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
    Bang, Su-Yeon
    Park, Silvia
    Kwag, Daehun
    Lee, Jong Hyuk
    Min, Gi-June
    Park, Sung-Soo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    Kim, Hee-Je
    CANCERS, 2023, 15 (06)
  • [38] Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective
    Pratz, Keith W.
    Chai, Xinglei
    Xie, Jipan
    Yin, Lei
    Nie, Xiaoyu
    Montez, Melissa
    Iantuono, Erica
    Downs, Lisa
    Ma, Esprit
    BLOOD, 2021, 138
  • [39] Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
    DiNardo, Courtney D.
    Lachowiez, Curtis A.
    Takahashi, Koichi
    Loghavi, Sanam
    Xiao, Lianchun
    Kadia, Tapan
    Daver, Naval
    Adeoti, Maria
    Short, Nicholas J.
    Sasaki, Koji
    Wang, Sa
    Borthakur, Gautam
    Issa, Ghayas
    Maiti, Abhishek
    Alvarado, Yesid
    Pemmaraju, Naveen
    Bravo, Guillermo Montalban
    Masarova, Lucia
    Yilmaz, Musa
    Jain, Nitin
    Andreeff, Michael
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kornblau, Steven
    Ravandi, Farhad
    Konopleva, Marina Y.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) : 2768 - +
  • [40] Low-dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
    Rong, Chunmeng
    Yang, Fang
    Chen, Yalu
    Wang, Ming
    Ai, Cheng
    Luo, Yuqing
    Gao, Panpan
    Weng, Yiqin
    Huang, Xiaguang
    Gu, Meier
    Huang, Weiping
    Xia, Yongming
    ONCOLOGY LETTERS, 2024, 27 (05)
12345